DRKS00026665招募中不适用

Prospective evaluation of the safety and efficacy of MR-guided moderately hypofractionated radiotherapy for inoperable malignant tumors of the lung, pleura, and mediastinum with a diameter > 5 cm and poor risk factors - MR-HYPOLUNG - MR-HYPOLUNG

Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum Grosshadern der LM0 个研究点目标入组 10 人开始时间: 2021年11月8日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Histologically confirmed, inoperable tumor of the lung, pleura or mediastinum with a diameter > 5 cm.
•2. Age = 18 years
•3. Limited pulmonary function and reserve (FEV = 1L and/or DLCO <40% or long-term oxygen therapy).
•4. ECOG Performance Status = 2
•5. Prior surgery, systemic and local ablative therapies (RFA, SABR, brachytherapy, etc.) are allowed.
•6. Indication for radiotherapy confirmed at the multidisciplinary tumor board.
•7. Patients are able to understand and willing to sign an IRB-approved informed consent document and adhere to the conditions of the study

•1. Known contraindications for radiotherapy e.g. severe comorbidities, interstitial lung disease etc.
•2. Significant overlap with a previously treated radiation volume - prior radiotherapy is generally allowed as long as all dose requirements are met in the composite plan (biologically effective doses are calculated for this purpose).
•3. Pregnant and/or breastfeeding.
•4. Medical or psychological impairments that do not allow proper informed consent or trial participation.
•5. Lack of legal capacity.

发起方

Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum Grosshadern der LM